will be much higher by Tuesday of next week. Close to the teens if not in the teens. Mark it.
FreeSeas Inc. (FREE) Through its subsidiaries, provides drybulk shipping services. Its vessels carry various drybulk commodities, such as iron ore, grain, and coal, as well as bauxite, phosphate, fertilizers, steel products, cement, sugar, and rice.
FREE has been on a near perfect downward trend to $0. Can FREE go any lower? We think, maybe not. FREE is on bounce play alert for the short-term. If any news or reversal in trend occurs, we will alert you on it.
Hope you did. If not ....I have good news. It is not too late and just the beginning of a massive run.
GBSN with the new 2 FDA approvals makes them a real competitor among the top 4 player. You can bet the current provider's for these test do not want to lose their market share. The best way to do that is buyout the one disrupting the market. Look for the market cap to quickly get to at least 40 Million and a buyout would be at 3 X that.
Take a look at GBSN competitors:
Cepheid - 2.25 Billion market cap - CPHD
Meridian Bioscience - 900 Million - VIVO
GenMark Diagnostics - 210 Million - GNMK
T2 Biosystems - 207 Million - TTOO
GBSN - 22 Million market cap. Significantly undervalued. On average approx $75,000 - 300,000 per year annual revenue per customer in this space. Just say 150K average per customer per year. GBSN should reach 300 customers in 2016 with new FDA approved additional testing. This would generate 45 Million in revenue per year. Say GBSN only gets half of that............it is still more than the current market cap!
assuming they get the other two approvals that are expected in the US......the share price should be about 25.00. If they get the EU approvals as well on the three you can add 15.00. I expect they will be acquired in the near future vs hiring their own sales force.